Litigation Details for In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation (N.D. Ohio 2025)

« Back to Dashboard

In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation (N.D. Ohio 2025)

Docket	1:24-md-03092	Date Filed	2025-05-12
Court	District Court, N.D. Ohio	Date Terminated
Cause	28:1332 Diversity-Product Liability	Assigned To	Philip
Jury Demand	Plaintiff	Referred To
Patents	8,475,832; 8,921,387
Link to Docket	External link to docket

Details for In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation (N.D. Ohio 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-05-12				External link to document
2024-06-14	100	Complaint	2009. The patent application was granted on July 2, 2013 (US 8,475,832 B2) (“‘832 patent”). The ‘832…Sublingual and Buccal Film Compositions, US Patent 8,475,832 B2 (indicating that the target range of pH…Jan. 24, 1995) (available at https://patents.google.com/patent/US5384333A/en) (last accessed June 7, …Alkermes, Inc. applied for a patent for that delivery system in 2005. Patent No. US 7919499 B2, Ehrich,…2011) (available at https://patents.google.com/patent/US7919499B2/en) (last accessed June 7,	External link to document

In re Suboxone Film Products Liability Litigation, MDL No. 3092: Litigation Summary and Risk Analysis

Last updated: October 30, 2026

The Suboxone film products-liability MDL concerns alleged dental injuries associated with buprenorphine/naloxone sublingual film. Plaintiffs generally allege that Indivior Inc., Indivior UK Ltd., and related entities failed to adequately warn patients and prescribers about the risk of severe dental disease, including caries, tooth loss, crowns, root canals, and extractions. The litigation is distinct from the earlier Suboxone antitrust MDL and does not primarily concern patent validity, generic entry, or Orange Book listings.

What is In re Suboxone Film Products Liability Litigation, 1:24-md-03092?

The proceeding is a multidistrict litigation consolidating federal product-liability actions involving Suboxone sublingual film. The Judicial Panel on Multidistrict Litigation transferred and centralized related actions for coordinated pretrial proceedings under 28 U.S.C. § 1407. The docket is designated MDL No. 3092. [1]

The central theory is that exposure of teeth to acidic or otherwise harmful components of the film can increase the risk of dental decay and other oral injury, and that the manufacturers allegedly knew or should have known about the risk before providing adequate warnings.

Item	Information
Litigation	In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation
MDL number	3092
Lead docket	1:24-md-03092
Product	Buprenorphine/naloxone sublingual film
Primary defendants	Indivior-related entities and affiliated product companies
Core claims	Failure to warn, design defect, negligence, strict liability, breach of warranty and related state-law claims
Alleged injuries	Dental caries, tooth decay, tooth loss, restorations, root canals, crowns and extractions
Litigation posture	Coordinated federal pretrial proceedings
Patent dispute	Not the principal subject of the MDL
Regulatory issue	Adequacy and timing of dental-risk warnings

What allegations are plaintiffs making against Suboxone manufacturers?

Plaintiffs allege that Suboxone film can contact the teeth and gums during administration and may contribute to dental injury. The complaints generally focus on three issues:

1. Whether the product’s formulation or administration method creates a material dental risk.
2. Whether the manufacturers had sufficient scientific, adverse-event or postmarketing information to identify that risk.
3. Whether the product labeling gave patients and prescribers adequate instructions to reduce the risk.

The claims are expected to vary by plaintiff because state-law standards differ. Typical causes of action include:

• Failure to warn or instruct.
• Strict products liability.
• Negligent design or manufacture.
• Negligent failure to test or monitor.
• Breach of express or implied warranty.
• Fraudulent concealment or misrepresentation.
• Consumer-protection claims.
• Loss of consortium and related derivative claims.

The defense is likely to contest general causation, specific causation, warning adequacy, alternative design, comparative fault, statute-of-limitations issues and the extent of claimed damages.

How did the FDA address dental risks associated with buprenorphine products?

The FDA issued a Drug Safety Communication in January 2022 warning that buprenorphine medicines dissolved in the mouth can cause dental problems, including tooth decay, cavities, oral infections and loss of teeth. The FDA recommended that patients rinse their mouths with water after the medicine has fully dissolved, wait at least one hour before brushing and maintain regular dental care. [2]

The FDA directed manufacturers to update product labeling. Suboxone prescribing information now includes warnings concerning dental problems and patient counseling on oral hygiene after administration. [3]

What is the regulatory significance of the FDA label change?

The label change is central to both sides of the litigation.

Plaintiffs are likely to argue that the FDA action confirms that a material risk existed and that earlier labeling was inadequate. They may use the timing of the FDA communication, adverse-event reports, scientific literature and internal safety evaluations to support notice and failure-to-warn claims.

Defendants are likely to argue that:

• The FDA evaluated the available evidence before requiring labeling changes.
• Current warnings provide an effective risk-reduction instruction.
• The FDA action does not establish that the product caused every alleged dental injury.
• Plaintiffs must prove individual exposure, medical causation and damages.
• The relevant state-law warning standard may be affected by federal regulatory action.

The FDA communication does not itself determine civil liability. It is evidence relevant to notice, warning adequacy, causation and risk management.

What is the current litigation status of MDL 3092?

The MDL process is designed to coordinate discovery, resolve common legal issues and select representative cases for potential bellwether trials. Centralization does not merge all claims into one case and does not determine liability for individual plaintiffs.

The principal procedural stages are expected to include:

• Appointment or confirmation of leadership counsel.
• Filing of a consolidated master complaint.
• Defendant answers or motions to dismiss.
• Plaintiff fact sheets.
• Medical-record and pharmacy-record discovery.
• Corporate, regulatory and scientific discovery.
• Expert discovery on general and specific causation.
• Bellwether selection.
• Summary-judgment motions.
• Potential bellwether trials, mediation or global settlement negotiations.

A bellwether verdict would not automatically establish liability in every transferred action. It would provide information about jury reaction, proof requirements, damages and settlement value.

No final merits judgment or nationwide settlement should be inferred merely from the creation of the MDL.

What evidence will determine liability in Suboxone dental-injury cases?

Product exposure and administration

Plaintiffs will need to establish that they used the relevant Suboxone film product, often through prescriptions, pharmacy records, patient testimony and medical records. Duration, dose, frequency and administration practices may affect both exposure and damages.

Dental history

Pre-existing dental disease will be a major issue. Relevant evidence may include:

• Dental records before and after Suboxone use.
• Prior caries, periodontal disease and restorations.
• Smoking, alcohol and drug-use history.
• Salivary or systemic medical conditions.
• Oral hygiene and brushing practices.
• Use of other medications associated with dry mouth.
• Timing of dental deterioration relative to film exposure.

Expert causation

Experts are likely to address whether the formulation can cause or materially contribute to dental injury, whether the risk differs from other buprenorphine delivery systems, and whether an individual plaintiff’s injury is attributable to Suboxone rather than competing causes.

The litigation will likely involve toxicology, dentistry, pharmacology, epidemiology, regulatory science and pharmaceutical formulation experts.

How strong is the plaintiffs’ warning case?

The plaintiffs’ strongest evidence is the FDA’s 2022 safety communication and subsequent labeling change. Those actions support an argument that dental risk was sufficiently important to require a formal warning and specific post-dose instructions.

The defense has several substantial counterarguments:

• The FDA warning does not establish causation for a particular dental condition.
• Dental disease has multiple common causes.
• Opioid-use-disorder patients may have pre-existing dental and health-risk factors.
• Compliance with post-dose rinsing and brushing instructions may vary.
• State-law warning claims require individualized proof.
• The learned-intermediary doctrine may limit claims based on physician warnings in some jurisdictions.
• Federal regulatory review may support, but does not necessarily compel, a finding of warning adequacy.

The strength of individual cases will depend heavily on documented pre-use dental condition, duration of exposure, post-use dental progression and the quality of alternative-cause evidence.

What defenses are likely to shape the MDL?

Federal preemption

Defendants may assert federal preemption, particularly where plaintiffs argue that the manufacturers should have used stronger labeling before FDA approval or before an FDA-approved change. The outcome will depend on the specific warning alleged, the regulatory record and the applicable preemption doctrine.

Learned intermediary doctrine

In jurisdictions applying the learned intermediary doctrine, defendants may argue that the duty ran to prescribing physicians rather than directly to patients. Plaintiffs may respond that the warning was inadequate for both physicians and patients or that the product required direct-use instructions.

Statute of limitations

Dental injuries may develop gradually. Defendants are likely to argue that some claims accrued when plaintiffs first learned of dental deterioration, received treatment or had reason to connect the injuries to Suboxone. Plaintiffs may invoke discovery-rule and fraudulent-concealment theories.

Alternative causation

Defendants are likely to focus on smoking, poor oral hygiene, pre-existing dental disease, dry mouth, nutrition, other drugs and delayed dental care. This defense could produce substantial variation among plaintiff cases.

Damages

Economic damages may include dental treatment, prosthetics, implants, medication and future care. Non-economic damages may involve pain, disfigurement and reduced quality of life. Proof of future dental expenses will require individualized expert analysis.

Does MDL 3092 involve patents, Orange Book listings or Paragraph IV challenges?

No. MDL 3092 is a product-liability proceeding, not a Hatch-Waxman patent case.

The proceeding should be separated from the patent and antitrust history surrounding Suboxone film. Patent disputes involving buprenorphine/naloxone film, formulation claims or manufacturing technology may affect market competition, but they do not resolve whether Suboxone caused a particular plaintiff’s dental injury.

Issue	Relevance to MDL 3092
Orange Book listing	Not the primary issue
Paragraph IV certification	Not the basis of the MDL
Patent expiration	Does not determine product-liability liability
Generic launch	Commercially relevant but legally separate
Formulation patents	Potentially relevant to product history and competition
Method-of-use patents	Not central to the dental-injury claims
Biosimilar risk	Not applicable; Suboxone is a small-molecule drug
FDA approval	Relevant to regulatory history and defenses

Which companies face commercial exposure?

The principal commercial exposure is concentrated in the manufacturers and entities involved in developing, marketing or distributing Suboxone film. The relevant corporate structure and time period will matter because responsibility may differ based on:

• Product ownership at the time of use.
• Marketing authorization.
• Manufacturing contracts.
• Label control.
• Distribution arrangements.
• Corporate transactions and successor liability.
• State-law allocation of liability.

Exposure cannot be estimated from the MDL number alone. A meaningful valuation requires the number of filed claims, claimant medical evidence, duration of use, injury severity, applicable state law, insurance coverage and settlement methodology.

What generic-entry risks exist for Suboxone film?

Generic competition is separate from the product-liability proceeding. Generic buprenorphine/naloxone films may face ordinary regulatory, manufacturing and intellectual-property issues, but a generic manufacturer’s liability profile may differ from the innovator’s.

Potential issues include:

• Whether the generic label must match the reference product.
• Whether federal law limits a generic manufacturer’s ability to change labeling independently.
• Whether plaintiffs sue generic manufacturers, brand manufacturers or both.
• Whether state law recognizes innovator-liability theories.
• Whether a generic product uses the same or a materially different film formulation.
• Whether pharmacy substitution affects product identification.

These issues can complicate allocation of claims among brand and generic manufacturers. They do not convert MDL 3092 into a patent case.

What litigation outcomes are most plausible?

The principal outcome paths are:

1. Dismissal of some claims. Courts may narrow fraud, consumer-protection, punitive-damages or time-barred claims.
2. Claim-by-claim resolution. Many cases may turn on dental records and specific causation rather than common evidence.
3. Bellwether trials. Representative trials could establish settlement benchmarks.
4. Targeted settlement. Defendants may resolve claims involving strong medical evidence while contesting weaker files.
5. Global or inventory-wide settlement. A broader agreement could follow substantial discovery and early trial results.
6. Continued individual litigation. If causation and damages vary materially, the MDL may return many cases to originating courts.

The FDA warning increases the importance of warning adequacy and notice evidence, but causation and damages will remain the principal case-specific barriers for plaintiffs.

Key Takeaways

• MDL No. 3092 concerns alleged dental injuries from Suboxone buprenorphine/naloxone film.
• The FDA’s 2022 dental-risk communication and updated labeling are central evidence.
• The litigation is separate from Suboxone patent, Orange Book and antitrust disputes.
• Plaintiff strength will depend on dental records, exposure history, alternative causes and expert causation testimony.
• Defendants are likely to pursue preemption, learned-intermediary, limitations, comparative-fault and causation defenses.
• The MDL creates coordinated pretrial proceedings but does not establish liability across all claims.
• Bellwether discovery and representative trials will likely determine settlement pressure and claim valuation.

FAQs About Suboxone Film Product-Liability Litigation

Can patients sue for tooth decay caused by Suboxone film?

Potentially. A plaintiff generally must prove product exposure, legally actionable conduct, medical causation, damages and a timely claim under the applicable state law.

Does the FDA warning prove that Suboxone caused a plaintiff’s dental injury?

No. The warning supports evidence concerning risk and notice, but each plaintiff generally must establish specific causation and damages.

Are Suboxone generic manufacturers included in the litigation?

Generic involvement depends on the complaint, product identification and applicable law. The MDL’s central allegations concern Suboxone film and its manufacturers, but liability may differ for brand and generic products.

Will an MDL settlement automatically compensate every Suboxone user?

No. An MDL settlement would require defined eligibility criteria, proof requirements and individual claim evaluation unless the agreement expressly provides otherwise.

Is Suboxone film still FDA-approved?

Yes. Buprenorphine/naloxone sublingual film remains an FDA-approved medication for opioid-use-disorder treatment, subject to prescribing information and dental-risk instructions. [3]

References

1. Judicial Panel on Multidistrict Litigation. (2024). In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092. United States Judicial Panel on Multidistrict Litigation.

2. U.S. Food and Drug Administration. (2022, January 12). FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. https://www.fda.gov/

3. Indivior Inc. (2024). Suboxone (buprenorphine and naloxone) sublingual film prescribing information. U.S. Food and Drug Administration.